拜耳 20250114-bayer-handout-jpm-2025.pdf

1、/Health for all,Hunger for none43rdAnnual J.P.Morgan Healthcare ConferenceHandoutJanuary 2025Cautionary Statements Regarding Forward-Looking Information2This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.The company assumes no

2、 liability whatsoever to update these forward-looking statements or to conform them to future events or developments.Various known and unknown risks,uncertainties and other factors could lead to material differences between the actual future results,financial situation,development or performance of

3、the company and the estimates given here.These factors include those discussed in Bayers public reports which are available on the Bayer website athttp:/ J.P.Morgan Healthcare Conference/Bayer PharmaceuticalsDelivering Sales Growth,Earnings and Cash Flow Guidance3Sales Growth(cpa)Core EPS20.2%26.9%2

4、3.4%-2%+4%+3%cpa=currency and portfolio adjustedBAYER GROUP4.00vs PY+1%vs PYFree Cash Flow-0.2bnvs PY9M 2024Sales Growth(cpa)EBITDA Margin(before special items)Crop SciencePharmaceuticalsConsumer HealthGrowth in Pharmaceuticals and Consumer Health offsetting headwinds in Crop Science/43rdAnnual J.P.

5、Morgan Healthcare Conference/Bayer PharmaceuticalsOur Ambition Through 20264GroupGrowth&Innovation:Crop Science:Outgrow market in core business;Improve profitability;Extend innovation leadership with annual portfoliorefresh and advancement of blockbuster technologiesPharmaceuticals:Support topline r

6、esilience during LoEs of major products;Drive productivity gains to support margins;Advance early assets to rebuild promising mid-/late pipelineConsumer Health:Grow above market;Deliver profitability at industry competitive margin level;Further build our iconic brands through innovation and commerci